---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-072838"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:22:06.289672+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Unicycive Therapeutics appoints Grassi & Co. as new auditor effective Aug 28, 2023

## Summary
- Grassi & Co. CPAs, P.C. appointed as independent registered public accounting firm on Aug 28, 2023, subject to client acceptance.
- Appointment follows resignation of prior auditor Mayer Hoffman McCann P.C., disclosed on July 31, 2023.
- No prior consultations with Grassi on accounting principles or audit opinions during 2022 or through June 30, 2023.
- No disagreements or reportable events occurred between company and previous auditor.
- Audit Committee approved the appointment.

## SEC filing metadata
- accession: 0001213900-23-072838
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 4.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023072838/0001213900-23-072838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023072838/ea184501-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-072838
- JSON: https://secwatch.observer/filing/0001213900-23-072838.json
- Plain text: https://secwatch.observer/filing/0001213900-23-072838.txt

## Key facts
- Auditor Changes
  Unicycive Therapeutics, Inc. engaged Grassi & Co. CPAs, P.C. as its auditor.
  - Action: engagement
  - Auditor: Grassi & Co. CPAs, P.C.
  source text: ugust 28, 2023, the Company appointed Grassi & Co. CPAs, P.C. (“ Grassi ”) as the Company’s new independent registered public accounting firm effective as of August 28, 2023, subject to Grassi’s completion of its client acceptance process. The Audit Committee of the board of directors of the Company approved the appointment of Grassi. During the fiscal year ended December 31, 2022 and the interim period from January 1, 2023 through June 30, 2023, neither the Company, nor anyone
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023072838/0001213900-23-072838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.